Resources | OncoC4

Phase 1 Study Of Gotistobart (BNT316/ONC-392) In Combination With Lutetium 177 VipivotideTetraxetan (Lu 177) In Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Gotistobart In Combination With Pembrolizumab In Patients With Advanced Melanoma Who Have Progressed On PD-1 Inhibitors With Or Without CTLA-4 Inhibitors

January 13, 2025

pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4antibodies

September 15, 2024

PRESERVE-004/GOG-3081 (NCT05446298): A Phase 2 randomized dose optimization trial of gotistobart, a pH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer

PRESERVE-004/GOG-3081 (NCT05446298): A Phase 2 randomized dose optimization trial of gotistobart, a pH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer

PHASE 2, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF GOTISTOBART + PEMBROLIZUMAB IN PLATINUM-RESISTANT OVARIAN CANCER (PROC)

January 04, 2024

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

November 01, 2023

Single agent Safety and Activities of Target preserving Anti CTLA 4 Antibody Gotistobart (ONC 392/BNT316) in PD –(L)1 Resistant Metastatic NSCLC and Population PK Analysis in Patients with Solid Tumors

September 22, 2023

Preserving CTLA-4 Checkpoint Function for Safer and More effective Immunotherapy

September 14, 2023

Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4– and PD-1–targeted immunotherapy

Safety and Clinical Activity of Target Preserving Anti-CTLA-4 Antibody ONC-392/BNT316 as Monotherapy in NSCLC Patients who Progressed on PD-(L)1 targeting Immunotherapy

PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 /BNT316 Versus Docetaxel in Metastatic Non-Small Cell LungCancers that Progressed on PD-1/PD-L1 Inhibitors (NCT05671510)

CD24-Siglec interactions in inflammatory diseases

November 08, 2022

Safety and Clinical Activities of ONC-392, a target preservinganti-CTLA-4 mAb, in Ovarian Cancer Patients Who Have Failed Multiple Lines of Systemic Therapies

November 08, 2022

Dose escalation of ONC-392, a target preserving anti-CTLA4 mAb, in combination with fixed dose of pembrolizumab in patients with advanced solid tumors and dose expansion in patients with IO-resistant melanoma

August 22, 2022

CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

November 10, 2021

Clinical protocol of an open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors

November 10, 2021

Pharmacokinetics of First and Repeated Dosing of Anti-CTLA-4 Monoclonal Antibody ONC-392 in Advanced Cancer Patients

November 10, 2021

First-in-human study of the first acid pH sensitive and recycling CTLA 4 antibody ONC392 that preserves the immune tolerance checkpoint to avoid immunotherapy related adverse events in patients with advanced solid tumor (PRESERVE 1, NCT04140526)

November 10, 2021

Molecular Insights on Safety and Anti-tumor Activity ofAnti-CTLA-4 Monoclonal Antibody ONC-392

February 09, 2021

Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma.

Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer.

Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.

January 24, 2020

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies.

January 01, 2020

Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.

August 01, 2019

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.

December 01, 2018

How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.

Uncoupling Therapeutic from Immunotherapy-related Adverse Effects for Safer and Effective Anti-CTLA-4 Antibodies in CTLA4 Humanized Mice.

September 01, 2014

Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity.

August 14, 2014

Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.

January 01, 2014

Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice.

Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction.

Targeting HIF1α eliminates cancer stem cells in hematological malignancies.

February 01, 2011

Sialoside-based pattern recognitions discriminating infections from tissue injuries.

January 01, 2009

CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses.

A dinucleotide deletion in CD24 confers protection against autoimmune diseases.

January 01, 2006

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.

January 01, 2005

Anti-human CTLA-4 monoclonal antibody promotes T cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies.

January 01, 2005

Human CTLA-4-knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.

December 09, 2003

CD24 is a genetic modifier for risk and progression of multiple sclerosis.